PHXM
PHAXIAM Therapeutics S.A.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$28.90M
P/E Ratio
—
EPS
$-39.05
Beta
1.96
52W High
$0.00
52W Low
$0.00
50-Day MA
$4.90
200-Day MA
$7.21
Dividend Yield
—
Profit Margin
-191.00%
Forward P/E
—
PEG Ratio
—
About PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. The company is headquartered in Lyon, France.
Fundamentals
| Revenue (TTM) | $5.97M |
| Gross Profit (TTM) | 0 |
| EBITDA | $-16.86M |
| Operating Margin | -3232.00% |
| Return on Equity | -38.60% |
| Return on Assets | -15.00% |
| Revenue/Share (TTM) | $1.87 |
| Book Value | $6.03 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -66.40% |
| Shares Outstanding | $6.07M |
| Float | $4.51M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Data last updated: 4/9/2026